From the laboratory to clinical treatment, the development of new drugs often takes over a decade and billions of dollars. Enhancing development efficiency while ensuring safety and precision has become a critical challenge for the global biotech industry.
As a pioneer in protein and antibody manufacturing, Leadgene Biomedical will showcase its integrated capabilities at the 2025 Bio Asia (OTC Center Joint Booth N905). The company will highlight three key technologies: the region-leading "Next-Generation Nanobody Screening Platform" (VHH Naïve Library Screening), the "C.STATION Automated Cell Line Development Platform," and its collaboration with SIDSCO Biomedical on "Animal Studies, Toxicology, and Tissue Validation." These one-stop services aim to help pharmaceutical companies overcome development bottlenecks.
"New drug development faces universal challenges of high costs and long timelines, and the quality and efficiency of front-end antibody development often determine the success of a project," said Leadgene Biomedical Chairman Dr. Chasel Yung-Chun Chuang.
Next-generation nanobodies, with their small size, high stability, and strong penetration, offer unique advantages. They can precisely target and inhibit critical sites hidden within protein structures that traditional antibodies struggle to reach, akin to equipping drugs with advanced GPS navigation to accurately attack malignant cells.
"Our proprietary screening platform can identify the most promising candidate antibodies at unprecedented speed, eliminating months of effort and seizing market opportunities," Chuang added.
In the biopharmaceutical field, finding stable and high-yield cell lines is another common bottleneck. Leadgene Biomedical has partnered strategically with CYTENA BPS to establish the Asia-Pacific region's first "C.STATION Automated Cell Line Development Platform."
CEO Dr. Louis Yu-Wei Cheng noted that what used to take at least six months can now be transformed into a standardized, high-efficiency system. "It's like upgrading a traditional factory into a precision automated semiconductor plant, offering a significant competitive edge in the time-sensitive biotech industry."
Through high-throughput and automated screening technologies, the platform not only reduces development timelines and labor costs but also accelerates the journey of new drugs from the lab to the market.
Leadgene Biomedical is not only advancing front-end drug development but also bridging the "last mile" of preclinical studies.
In January 2025, the company acquired 100% equity in SIDSCO Biomedical, extending its one-stop service capabilities downstream to include animal studies and toxicology validation. Chairman Dr. Yung-Chun Chuang emphasized that through vertical integration of CDMO (Contract Development and Manufacturing Organization) and CRO (Contract Research Organization) services, the company has evolved into a more comprehensive CRDMO.
This enables even small research teams to access resource integration efficiencies comparable to those of international giants. It also fills a critical gap in Taiwan's biotech industry chain, connecting research and validation.
Beyond pursuing technological innovation, Leadgene Biomedical remains committed to corporate social responsibility.
In response to the global challenges posed by emerging viruses, the company recently donated to the National Cheng Kung University College of Medicine to help establish a BSL-2 (Biosafety Level 2) compliant virus laboratory.
This tangible support for top-tier academic research aims to cultivate the next generation of biotech talent, bridging the gap between academia and industry.
It also strengthens Taiwan's scientific foundation for addressing potential future pandemics. Leadgene Biomedical aspires to be a key force in enhancing the resilience of Taiwan's biotech industry chain and driving global biotech and medical advancements.
